Cerevel Therapeutics Holdings, Inc. (CERE) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Cambridge, MA, United States. वर्तमान CEO हैं Ronald C. Renaud Jr.,.
CERE के पास है IPO तिथि 2020-07-30, 355 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Capital Marke, बाजार पूंजीकरण $8.19B.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases including schizophrenia, epilepsy, Parkinson's disease, and psychiatric disorders. The company's pipeline includes several lead programs in clinical development, such as emraclidine for schizophrenia, Darigabat for drug-resistant epilepsy and anxiety, and Tavapadon for Parkinson's disease, alongside multiple earlier-stage candidates targeting conditions like dementia-related apathy, substance use disorder, and major depressive disorder. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cerevel leverages multiple molecular mechanisms and receptor targets to address critical unmet needs in central nervous system disorders.
